Document is current
Any future updates will be listed below
-
Authors
Akiyama, Hiroki https://orcid.org/0000-0003-2627-1055
Kantarjian, Hagop
Jabbour, Elias
Issa, Ghayas
Haddad, Fadi G.
Short, Nicholas J.
Hu, Shimin
Ishizawa, Jo
Andreeff, Michael
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
-
Funding
Funding for this research was provided by:
The University of Texas MD Anderson Cancer Center Support Grant (CA016672)
The University of Texas MD Anderson Cancer Center MDS/AML Moon Shot
The Charif Souki cancer research grant
Leukemia Texas
- License Information
-
More Information
Article History
Received: 30 January 2024
Revised: 21 April 2024
Accepted: 30 April 2024
First Online: 15 May 2024
Declarations
:
: HMK reported research funding from Shenzhen Target Rx, Pfizer, Novartis, Labcorp, KAHR medical, Ipsen Biopharmaceuticals, Curis, Biologix, Astellas, Ascentage, Amphista, Amgen, Abbvie, Stemline, Takeda, Daiichi-Sankyo, Immunogen, Jazz Pharmaceuticals, Bristol Myers Squibb, ARIAD, Astex Pharmaceuticals, Agios, Cyclacel, and honoraria from Shenzhen Target Rx, Pfizer, Novartis, Labcorp, KAHR medical, Ipsen Biopharmaceuticals, Curis, Biologix, Astellas, Ascentage, Amphista, Amgen, Abbvie, Stemline, Takeda, Precision BioSciences, ARIAD, Immunogen, Orsenix, Agios, Actinium Pharmaceuticals, outside the study. EJ reported research funding from Novartis, Hikma, Takeda, Pfizer, Genentech, Amgen, Astex, Adaptive Biotech, Ascentage, Bristol Myers Squibb, Abbvie, Jazz Pharmaceuticals, consulting fee from Novartis, Hikma, Takeda, Pfizer, Genentech, Amgen, Astex, Adaptive Biotech, Ascentage, Bristol Myers Squibb, Abbvie, Jazz Pharmaceuticals, and honoraria from Hikma, Takeda, Pfizer, Genentech, Amgen, Astex, Adaptive Biotech, Ascentage, Bristol Myers Squibb, Abbvie, outside this study. GI reported research funding from NuProbe, Novartis, Syndax, Astex, Merck, Kura Oncology, Celgene, Cullinan Oncology, and consulting fee from NuProbe, Novartis, Syndax, Kura Oncology, Abbvie, outside this study. NJS reported research funding from Stemline Therapeutics, Astellas, Takeda, and consulting fee from Novartis, Takeda, AstraZeneca, Pfizer, Amgen, and honoraria from Amgen, outside this study. MA reported research funding from Daiichi Sankyo, Brest Cancer Research Foundation, AstraZeneca, Oxford Biomedical UK, Eterna, SentiBio, Pinot Bio, Syndax, and advisory board fee from Cancer UK, Leukemia & Lymphoma Society, Aptose, German Research Council, NCI, CLL Foundation, Eterna, and stock or stock options from Reata, Aptose, Eutropics, SentiBio, Chimerix, outside this study. KS reported research funding from Novartis, EnLiven, consulting fee from Novartis, and honoraria from Otsuka Pharmaceuticals, Amgen, advisory board fee from Novartis, Pfizer, Daiichi-Sankyo, outside this study. The rest of the authors did not have conflicts of interest to report.
